-$0.41 Earnings Per Share Expected for Translate Bio Inc (NASDAQ:TBIO) This Quarter

Equities research analysts expect that Translate Bio Inc (NASDAQ:TBIO) will post ($0.41) earnings per share (EPS) for the current quarter, according to Zacks. Six analysts have issued estimates for Translate Bio’s earnings. The lowest EPS estimate is ($0.57) and the highest is ($0.33). Translate Bio reported earnings per share of ($0.57) in the same quarter last year, which would suggest a positive year over year growth rate of 28.1%. The company is scheduled to announce its next earnings report on Wednesday, July 29th.

On average, analysts expect that Translate Bio will report full-year earnings of ($1.40) per share for the current year, with EPS estimates ranging from ($1.62) to ($1.24). For the next financial year, analysts expect that the business will post earnings of ($1.44) per share, with EPS estimates ranging from ($1.63) to ($1.19). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Translate Bio.

Translate Bio (NASDAQ:TBIO) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.44) by $0.20. Translate Bio had a negative return on equity of 63.61% and a negative net margin of 859.22%. The company had revenue of $4.65 million during the quarter, compared to the consensus estimate of $2.23 million.

Several analysts have recently weighed in on TBIO shares. SVB Leerink boosted their target price on Translate Bio from $21.00 to $30.00 and gave the company an “outperform” rating in a report on Friday, June 26th. Roth Capital boosted their target price on Translate Bio from $25.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, June 23rd. Jefferies Financial Group boosted their target price on Translate Bio from $17.00 to $29.00 and gave the company a “buy” rating in a report on Tuesday, June 23rd. Zacks Investment Research upgraded Translate Bio from a “hold” rating to a “strong-buy” rating and set a $22.00 price target on the stock in a research report on Wednesday, July 1st. Finally, SunTrust Banks began coverage on Translate Bio in a research report on Friday, June 26th. They issued a “buy” rating and a $40.00 price target on the stock. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $31.14.

In other news, major shareholder Baupost Group Llc/Ma purchased 500,000 shares of the firm’s stock in a transaction dated Friday, June 26th. The shares were acquired at an average price of $22.00 per share, with a total value of $11,000,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Human Genetic Therapies Shire sold 108,472 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $19.86, for a total value of $2,154,253.92. The disclosure for this sale can be found here. Insiders have sold a total of 6,973,550 shares of company stock worth $144,086,787 in the last three months. Corporate insiders own 12.30% of the company’s stock.

Several large investors have recently made changes to their positions in TBIO. HighTower Advisors LLC purchased a new stake in Translate Bio in the 1st quarter valued at approximately $133,000. Wells Fargo & Company MN lifted its stake in Translate Bio by 35.8% in the 1st quarter. Wells Fargo & Company MN now owns 21,446 shares of the company’s stock valued at $214,000 after buying an additional 5,656 shares in the last quarter. Aperio Group LLC purchased a new stake in Translate Bio in the 1st quarter valued at approximately $101,000. Nuveen Asset Management LLC lifted its stake in Translate Bio by 17.7% in the 1st quarter. Nuveen Asset Management LLC now owns 138,522 shares of the company’s stock valued at $1,381,000 after buying an additional 20,855 shares in the last quarter. Finally, Invesco Ltd. purchased a new stake in Translate Bio in the 1st quarter valued at approximately $509,000. 83.92% of the stock is currently owned by institutional investors and hedge funds.

Shares of Translate Bio stock traded down $0.44 on Friday, hitting $15.19. The stock had a trading volume of 1,551,167 shares, compared to its average volume of 1,797,509. Translate Bio has a 52-week low of $6.80 and a 52-week high of $28.09. The company has a current ratio of 4.12, a quick ratio of 4.12 and a debt-to-equity ratio of 0.08. The stock has a market cap of $955.59 million, a price-to-earnings ratio of -8.94 and a beta of 0.52. The company’s 50 day moving average price is $18.02 and its 200 day moving average price is $12.76.

About Translate Bio

Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.

Read More: What is the Coverage Ratio?

Get a free copy of the Zacks research report on Translate Bio (TBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Translate Bio (NASDAQ:TBIO)

Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.